Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART-PRO: Dolutegravir + Lamivudine Guided by Proviral Genotype
NCT03539224Phase 2Unknown
- Sponsor
- Hospital La Paz Institute for Health Research
- Start
- Nov 2017
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dolutegravir, lamivudine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Hospital La Paz Institute for Health Research. Status: unknown.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03539224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03539224.